Equity and capacity to benefit from early access to medicines schemes
Abstract Many diseases, especially rare ones, have not gained the attention or support needed to attract dedicated research interest to be able to develop successful medicines. There is, thus, a significant unmet clinical need, not all of which is (or indeed can be) addressed through the evaluation...
Saved in:
| Main Authors: | Sarah J. L. Edwards, Paul Aliu, Joe Brierley, Søren Holm, Peter J. Pitts |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | International Journal for Equity in Health |
| Online Access: | https://doi.org/10.1186/s12939-025-02416-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Access and benefit sharing: streamlining legal frameworks for global health equity
by: Ayelet Berman, et al.
Published: (2025-01-01) -
Who benefits? Health equity and the Translational Science Benefits Model
by: Anna La Manna, et al.
Published: (2025-04-01) -
Advancing Equity and Accessibility in Eyecare
by: Anthony Obiyom Kamalu, et al.
Published: (2025-03-01) -
Internet Access Equity Policy Is the Internet Access Equity Policy Through USO Funds effective?
by: Rossi Adi Nugroho, et al.
Published: (2019-06-01) -
Intersectionality, equity-mindedness, and access to care
by: Naomi W. Nishi, et al.
Published: (2025-07-01)